The main directions and problems in the development of a vaccine against Toxoplasma gondii

Toxoplasma gondii is known to cause congenital infection in humans, animals, and severe illness in immunocompromised individuals. Therefore, the development of vaccines against the parasite is necessary. Despite significant advances in the development of effective vaccines against toxoplasmosis, the search for new vaccination strategies remains challenging. Over the past few years, various experimental approaches have shown that the development of a vaccine against T. gondii is possible. This review summarizes the achievements in the development of T. gondii vaccines and the main obstacles to the creation of a safe, effective and long-lasting vaccine. Successes and failures in the development and testing of candidate vaccines are also discussed. 

1. Sergiev V.P., Lobzin Yu.V., Kozlov S.S. Human parasitic diseases (protozoan and helminthiasis) // Foliant Publishing House, 2016: 640. (in Russian)].

2. Costa-Silva T.A., Borges M.M., Galhardo C.S., Pereira-Chioccola V.L. Immunization with excreted/secreted proteins in AS/n mice activating cellular and humoral response against Toxoplas-ma gondii infection // Acta Trop. 2012; 124:203–209. DOI: 10.1016/j.actatropica.2012.08.013.

3. Wang Y., Zhang D., Wang G., Yin H., Wang M. Immunization with excreted-secreted antigens reduces tissue cyst formation in pigs. Parasitol. Res. 2013; 112: 3835-3842. DOI: 10.1007/s00436-013-3571-4.

4. Buxton D., Innes E.A. A commercial vaccine for ovine toxoplasmosis // Parasitology. 1995;110 Suppl: 11-6. DOI: 10.1017/s003118200000144x

5. Dubey J.P. Toxoplasmosis in sheepthe last 20 years // Vet. Parasitol. 2009; 163: 1-14. DOI: 10.1016/j.vetpar.2009.02.026.

6. Chu K.B., Quan F.S. Advances in Toxoplasma gondii Vaccines: Current Strategies and Challenges for Vaccine Development // Vaccines (Basel). 2021; 9(5): 413. DOI: 10.3390/vaccines9050413.

7. Goncharov D.B., Mezentseva M.V., Surgucheva I.M., Kobets N.V., Ignatova N.G., Shcherbenko V.E., Narovlyansky A.N. Cytokine production in experimental toxoplasmosis // Med Parasitol (Mosk). 2008; 1: 16-19. (in Russian)]

8. Kobets N.V., Zaitseva L.G., Goncharov D.B., Gubareva E.V., Mezentseva M.V., Kireeva I.V., Surgucheva I.M., Samoylenko I.I. Immune response in toxoplasmosis after mucosal immunization with Toxoplasma gondii antigens // Med Parasitol (Mosk). 2010; 1: 10-14 (in Russian)]

9. Kobets N.V., Domonova E.A., Goncharov D.B., Mezentseva M.V., Silveistrova O.Yu., Gubareva E.V., Shapoval I.M., Ievleva E.S. Cellular mechanisms of control of Toxoplasma gondii dissemination during parenteral and oral infection. // Med Parasitol (Mosk). 2012; 4: 21-27. (in Russian)]

10. Xia D., Sanderson S.J., Jones A.R., Prieto J.H., Yates J.R., Bromley E., Tomley F.M., Lal K., Sinden R.E., Brunk B.P., Roos D.S., Wastling J.M. The proteome of Toxoplasma gondii: integration with the genome provides novel insights into gene expression and annotation // Genome Biol. 2008; 9(7): R116. DOI: 10.1186/gb-2008-9-7-r116.

11. Ma G.Y., Zhang J.Z., Yin G.R., Zhang J.H., Meng X.L., Zhao F. Toxoplasma gondii: proteomic analysis of antigenicity of soluble tachyzoite antigen. Exp. Parasitol. 2009; 122: 41–46. DOI: 10.1016/j.exppara.2009.01.011.

12. Weiss L.M., Ma Y.F., Takvorian P.M., Tanowitz H.B., Wittner M. Bradyzoite development in Toxoplasma gondii and the hsp70 stress response // Infect. Immun. 1998; 66: 3295-3302.

13. Silva N.M., Gazzinelli R.T., Silva D.A., Ferro E.A., Kasper L.H., Mineo J.R. Expression of Toxoplasma gondiispecific heat shock protein 70 during in vivo conversion of bradyzoites to tachyzoites // Infect. Immun. 1998; 66: 3959-3963.

14. Czarnewski P., Araújo E.C.B., Oliveira M.C., Mineo T.W.P., Silva N.M. Recombinant TgHSP70 immunization protects against Toxo-plasma gondii brain cyst formation by enhancing inducible nitric oxide expression // Front. Cell Infect. Microbiol. 2017; 7: 142. DOI: 10.3389/fcimb.2017.00142.

15. Onile O.S., Ojo G.J., Oyeyemi B.F., Agbowuro G.O., Fadahunsi A.I. Development of multiepitope subunit protein vaccines against Toxoplasma gondii using an immunoinformatics approach // NAR Genom Bioinform. 2020; 2: lqaa048. DOI: 10.1093/nargab/lqaa048.

16. Zhang N.Z., Xu Y., Wang M., Chen J., Huang S.Y., Gao Q., Zhu X.Q. Vaccination with Toxoplasma gondii calciumdependent protein kinase 6 and rhoptry protein 18 encapsulated in poly(lactidecoglycolide) microspheres induces longterm protective immunity in mice // BMC Infect Dis. 2016; 16: 168. DOI: 10.1186/s12879-016-1496-0.

17. Foroutan M., Ghaffarifar F. Calcium-de-pendent protein kinases are potential targets for Toxoplasma gondii vaccine // Clin. Exp. Vaccin. Res. 2018; 7: 24-36. DOI: 10.7774/cevr.2018.7.1.24.

18. Majidiani H., Soltani S., Ghaffari A.D., Sabaghan M., Taghipour A., Foroutan M. Indepth computational analysis of calciumdependent protein kinase 3 of Toxoplasma gondii provides promising targets for vaccination // Clin. Exp. Vaccin. Res. 2020; 9: 146–158. DOI: 10.7774/cevr.2020.9.2.146.

19. Dodangeh S., Fasihi-Ramandi M., Daryani A., Valadan R., Asgarian-Omran H., Hosseininejad Z., Nayeri Chegeni T., Pagheh A.S., Javidnia J., Sarvi S. Protective efficacy by a novel multiepitope vaccine, including MIC3, ROP8, and SAG1, against acute Toxoplasma gondii infection in BALB/c mice // Micro. Pathog. 2021; 153: 104764. DOI: 10.1016/j.micpath.2021.104764.

20. Warner R.C., Chapman R.C., Davis B.N., Davis P.H. Review of dna vaccine approaches against the parasite Toxoplasma gondii // J. Parasitol. 2021; 107: 882-903. DOI: 10.1645/20-157.

21. Kutzler M.A., Weiner D.B. DNA vaccines: ready for prime time // Nat. Rev. Genet. 2008; 9: 776-788. DOI: 10.1038/nrg2432.

22. El Bissati K., Zhou Y., Paulillo S.M., Raman S.K., Karch C.P., Reed S., Estes A., Estes A., Lykins J., Burkhard P., McLeod R. Engineering and characterization of a novel Self Assembling Protein for Toxoplasma peptide vaccine in HLA-A*11:01, HLA-A*02:01 and HLA-B*07:02 transgenic mice // Sci. Rep. 2020; 10: 16984. DOI: 10.1038/s41598-020-73210-0.

23. El Bissati K., Chentoufi A.A., Krishack P.A., Zhou Y., Woods S., Dubey J.P., Vang L., Lykins J., Broderick K.E., Mui E., Suzuki Y., Sa Q., Bi S., Cardona N., Verma S.K., Fraczek L., Reardon C.A., Sidney J., Alexander J., Sette A., Vedvick T., Fox C., Guderian J.A., Reed S., Roberts C.W., McLeod R. Adjuvanted multiepitope vaccines protect HLA-A*11:01 transgenic mice against Toxoplasma gondii // JCI Insight. 2016; 1: e85955. DOI: 10.1172/jci.insight.85955.

24. El Bissati K. et al. Effectiveness of a novel immunogenic nanoparticle platform for Toxoplasma peptide vaccine in HLA transgenic mice. Vaccine. 2014;32:3243-3248. DOI: 10.1016/j.vaccine.2014.03.092.

25. El Bissati K., Zhou Y., Dasgupta D., Cobb D., Dubey J.P., Burkhard P., Lanar D.E., McLeod R. Protein nanovaccine confers robust immunity against Toxoplasma // Vaccines. 2017; 2: 24. DOI: 10.1038/s41541-017-0024-6.

26. Roozbehani M., Falak R., Mohammadi M., Hemphill A., Razmjou E., Meamar A.R., Masoori L., Khoshmirsafa M., Moradi M., Gharavi M.J. Characterization of a multi-epitope peptide with selective MHC-binding capabilities encapsulated in PLGA nanoparticles as a novel vaccine candidate against Toxoplasma gondii infection // Vaccine. 2018; 36: 6124-6132. DOI: 10.1016/j.vac-cine.2018.08.068.

27. Luo F., Zheng L., Hu Y., Liu S., Wang Y., Xiong Z., Hu X., Tan F. Induction of Protective Immunity against Toxoplasma gondii in Mice by Nucleoside Triphosphate HydrolaseII (NTPase-II) Selfamplifying RNA Vaccine Encapsulated in Lipid Nanoparticle (LNP) // Front Microbiol. 2017; 8: 605. DOI: 10.3389/fmicb.2017.00605.

28. Pardi N., Hogan M.J., Weissman D. Recent advances in mRNA vaccine technology // Curr. Opin. Immunol. 2020; 65: 14-20. DOI: 10.1016/j.coi.2020.01.008.

29. Maeda Y., Kinoshita T. Structural remodeling, trafficking and functions of glycosylphos-phatidylinositol-anchored proteins // Prog. Lipid Res. 2011; 50: 411-424. DOI: 10.1016/j.plip-res.2011.05.002.

30. Debierre-Grockiego F., Campos M.A., Azzouz N., Schmidt J., Bieker U., Resende M.G., Mansur D.S., Weingart R., Schmidt R.R., Golenbock D.T., Gazzinelli R.T., Schwarz R.T. Activation of TLR2 and TLR4 by glycosylphosphatidylinositols derived from Toxoplasma gondii // J. Immunol. 2007; 179: 1129-1137. DOI: 10.4049/jimmunol.179.2.1129.

31. Astronomo R.D., Burton D.R. Carbohydrate vaccines: developing sweet solutions to sticky situations // Nat. Rev. Drug Discov. 2010; 9: 308-324. DOI: 10.1038/nrd3012.

32. Li Y., Liu Y., Xiu F., Wang J., Cong H., He S., Shi Y., Wang X., Li X., Zhou H. Characterization of exosomes derived from Toxoplasma gondii and their functions in modulating immune responses // Int. J. Nanomed. 2018; 13: 467-477. DOI: 10.2147/IJN.S151110.

33. Aline F., Bout D., Amigorena S., Roingeard P., Dimier-Poisson I. Toxoplasma gondii antigen-pulsed-dendritic cellderived exosomes induce a protective immune response against T. gondii infection // Infect. Immun. 2004; 72: 4127-4137. DOI: 10.1128/IAI.72.7.4127-4137.2004.

34. Santos P., Almeida F. Exosome-based vaccines: history, current state, and clinical trials. Front. Immunol // 2021; 12: 711565. DOI: 10.3389/fimmu.2021.711565.

35. Yektaeian N., Malekpour A., Atapour A., Davoodi T., Hatam G. Genetic immunization against toxoplasmosis: a review article // Micro. Pathog. 2021; 155: 104888. DOI: 10.1016/j.mic-path.2021.104888.

36. Attias M., Teixeira D.E., Benchimol M., Vommaro R.C., Crepaldi P.H., De Souza W. The lifecycle of Toxoplasma gondii reviewed using animations // Parasit. Vectors. 2020; 13: 588. DOI: 10.1186/s13071-020-04445-z.

37. Cong H. et al. Human immunome, bio-informatic analyses using HLA supermotifs and the parasite genome, binding assays, studies of human T cell responses, and immunization of HLA-A*1101 transgenic mice including novel adjuvants provide a foundation for HLA-A03 restricted CD8+ T cell epitope based, adjuvanted vaccine protective against Toxoplasma gondii. Immunome Res. 2010;6:12. DOI: 10.1186/1745-7580-6-12.

38. Cong H., Mui E.J., Witola W.H., Sidney J., Alexander J., Sette A., Maewal A., McLeod R. Toxoplasma gondii superinfection and virulence during secondary infection correlate with the exact ROP5/ROP18 allelic combination // mBio. 2015; 6: e02280. DOI: 10.1128/mBio.02280-14.

39. Dao A., Fortier B., Soete M., Plenat F., Dubremetz J.F. Successful reinfection of chronically infected mice by a different Toxoplasma gondii genotype // Int. J. Parasitol. 2001; 31: 63-65. DOI: 10.1016/S0020-7519(00)00151-X.

40. Cong H., Mui E.J., Witola W.H., Sidney J., Alexander J., Sette A., Maewal A., McLeod R. Human immunization with a polymorphic malaria vaccine candidate induced antibodies to conserved epitopes that promote functional anti-bodies to multiple parasite strains // J. Infect. Dis. 2018; 218: 35-43. DOI: 10.1093/infdis/jiy170.

41. Tu V., Mayoral J., Sugi T., Tomita T., Han B., Ma Y.F., Weiss L.M. Enrichment and proteomic characterization of the cyst wall from in vitro Toxoplasma gondii cysts // mBio. 2019; 10(2): e00469-19. DOI: 10.1128/mBio.00469-19.

42. Waldman B.S. et al. Identification of a master regulator of differentiation in toxoplasma. Cell. 2020;180:359-372.e316. DOI: 10.1016/j.cell.2019.12.013.

43. Inclan-Rico J.M., Siracusa M.C. First responders: innate immunity to helminths // Trends Parasitol. 2018; 34: 861–880. DOI: 10.1016/j.pt.2018.08.007.

44. Buxton D. Toxoplasmosis: the first commercial vaccine // Parasitol. Today. 1993; 9: 335-337. DOI: 10.1016/0169-4758(93)90236-9.

45. Sander V., Angel S.O., Clemente M. In Prospects of Plant-Based Vaccines in Veterinary Medicine (ed. MacDonald, J.). Springer International Publishing, 2018: 89–120.

46. Sacks D.L., Peters N.C., Bethony J.M. In The Vaccine Book, 2nd edn. (eds. Bloom, B. R. & Lambert, P.-H.). Academic Press, 2016: Ch. 17, 331–360.

47. Sander V.A., Sánchez López E.F., Mendoza Morales L., Ramos Duarte V.A., Corigliano M.G., Clemente M. Use of veterinary vaccines for livestock as a strategy to control foodborne parasitic diseases // Front. Cell Infect. Microbiol. 2020; 10: 288. DOI: 10.3389/fcimb.2020.00288.

48. Freyre A., Choromanski L., Fishback J.L., Popiel I. Immunization of cats with tissue cysts, bradyzoites, and tachyzoites of the T-263 strain of Toxoplasma gondii // J. Parasitol. 1993; 79: 716-719. DOI: 10.2307/3283610.

49. Ramakrishnan C., Maier S., Walker R.A., Rehrauer H., Joekel D.E., Winiger R.R., Basso W.U., Grigg M.E., Hehl A.B., Deplazes P., Smith N.C. An experimental genetically attenuated live vaccine to prevent transmission of Toxoplasma gondii by cats // Sci. Rep. 2019; 9: 1474. DOI: 10.1038/s41598-018-37671-8.

50. Sykes D., Rychtář J. A game-theoretic approach to valuating toxoplasmosis vaccination strategies // Theor. Popul. Biol. 2015; 105: 33-38. DOI: 10.1016/j.tpb.2015.08.003.